山药多糖调控mir-107改善妊娠期糖尿病脂肪组织胰岛素抵抗的机制研究

妊娠期糖尿病可使孕产妇与胎儿的患病率和病死率增加，严重影响母婴的健康。然而，妊娠期糖尿病发生时期特殊、发病机制复杂、治疗手段有限。我们前期研究发现mir-107与妊娠 糖尿病胰岛素抵抗密切相关；药食同源山药提取物（山药多糖）对妊娠糖尿病有显著防治作用。本项目拟在前期研究基础上，首先利用妊娠期糖尿病小鼠模型，给予慢病毒转染，分别过表达或抑制mir-107，以明确mir-107在妊娠糖尿病胰岛素抵抗中的作用；其次，利用脂肪细胞进行体外细胞实验，阐明mir-107对Caveolae1-IRS-pAkt/Insig1-SCAP-SREBP信号通路轴的调节机制；最后，明确山药多糖对妊娠糖尿病胰岛素抵抗的干预效应及mir-107的调节机制。这将为深入阐明妊娠期糖尿病胰岛素抵抗的发生机制及开发安全、有效、便捷的治疗药物提供一条新的思路和途径。

Gestational diabetes can increase maternal and fetal morbidity and mortality, which induces serious impact on maternal and infant health. However, it occurs at pregnant special time with complicated pathogenesis, treatment is restricted. Our previous studies have found that mir-107 is closely related to the gestational diabetes insulin resistance. Edible medicine yam extract polysaccharide (yam) plays a significant role in preventing gestational diabetes. Based on the previous research, firstly, this project uses gestational diabetes mice model, gives the slow virus transfection to overexpress or inhibit of mir-107, in order to make clear the role of mir-107 in gestational diabetes insulin resistance. Secondly, using adipocyte cells in vitro experiments to clarify the mechanism of mir-107 targeting Caveolae1-IRS-pAkt/ Insig1-SCAP-SREBP signaling pathways axis . Finally, to illuminate the intervention effect of yam polysaccharide on gestational diabetes mellitus insulin resistance and the regulation mechanism of mir-107. This will for further expound the mechanism of gestational diabetes insulin resistance and provide a new train of thought and way in finding safe, effective and convenient treatment for gestational diabetes.